Danaher slips as investors weigh soft diagnostics trends and Masimo integration risk

Danaher Corporation (DHR) is down 3.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is that investors are still focused on Danaher’s muted underlying growth profile, especially weakness in diagnostics, while also factoring in the balance-sheet and integration risks tied to the recent Masimo acquisition. This could also be because traders are repositioning ahead of the company’s next earnings report later this month. ([investors.danaher.com](https://investors.danaher.com/2026-04-21-Danaher-Reports-First-Quarter-2026-Results?asPDF=))

Details:

In first-quarter 2026 results, revenue rose 3.5% to about $6.0 billion, but core revenue increased only 0.5%, suggesting underlying demand was much softer than the headline growth rate. ([investors.danaher.com](https://investors.danaher.com/2026-04-21-Danaher-Reports-First-Quarter-2026-Results?asPDF=))

The Diagnostics segment was the main weak spot, with total sales down 1.5% and core sales down 4.0% year over year, which can pressure sentiment in a company that is heavily exposed to that market. ([investors.danaher.com](https://investors.danaher.com/2026-04-21-Danaher-Reports-First-Quarter-2026-Results?asPDF=))

Danaher completed its acquisition of Masimo on June 10, 2026, and the deal adds execution risk as investors assess integration, synergies, and the effect of acquisition financing on future results. ([investors.danaher.com](https://investors.danaher.com/2026-06-10-Danaher-Completes-Acquisition-of-Masimo-Corporation?utm_source=openai))

The company has scheduled its second-quarter 2026 earnings call for July 21, 2026, so some of today’s move may reflect caution ahead of fresh guidance and updated commentary. ([investors.danaher.com](https://investors.danaher.com/press-releases?l=100&utm_source=openai))

Sources:

Danaher investor relations, SEC, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DHR Insider Trading Activity

$DHR insiders have traded $DHR stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $DHR stock by insiders over the last 6 months:

GREGORY M MILOSEVICH (Executive Vice President) sold 1,320 shares for an estimated $274,574
ALAN G SPOON sold 1,358 shares for an estimated $237,206

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive DHR Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$DHR Hedge Fund Activity

We have seen 841 institutional investors add shares of $DHR stock to their portfolio, and 1,082 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL RESEARCH GLOBAL INVESTORS added 8,322,198 shares (+1445.9%) to their portfolio in Q1 2026, for an estimated $1,556,583,913
CAPITAL INTERNATIONAL INVESTORS removed 4,231,295 shares (-23.2%) from their portfolio in Q1 2026, for an estimated $791,421,416
HOLOCENE ADVISORS, LP added 3,099,516 shares (+329.9%) to their portfolio in Q1 2026, for an estimated $579,733,472
FMR LLC added 3,027,600 shares (+15.5%) to their portfolio in Q1 2026, for an estimated $566,282,304
BESSEMER GROUP INC removed 2,060,465 shares (-98.3%) from their portfolio in Q1 2026, for an estimated $385,389,373
AGF MANAGEMENT LTD removed 1,958,435 shares (-99.8%) from their portfolio in Q1 2026, for an estimated $366,305,682
MILLENNIUM MANAGEMENT LLC removed 1,863,602 shares (-91.1%) from their portfolio in Q1 2026, for an estimated $348,568,118

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DHR Government Contracts

We have seen $131,094,798 of award payments to $DHR over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

IN-VITRO REAGENTS - VISN 15, ORDERING PERIOD ONE: $2,952,609
MICROBIOLOGY REAGENTS & CONSUMABLES ADD CLAUSE 852.222-71 - COMPLIANCE WITH EXECUTIVE ORDER 13899: $2,353,640
MRSA REAGENTS: $1,655,465

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$DHR Analyst Ratings

Wall Street analysts have issued reports on $DHR in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 01/29/2026
Jefferies issued a "Buy" rating on 01/29/2026

To track analyst ratings and price targets for $DHR, check out Quiver Quantitative's $DHR forecast page.

$DHR Price Targets

Multiple analysts have issued price targets for $DHR recently. We have seen 14 analysts offer price targets for $DHR in the last 6 months, with a median target of $230.0.

Here are some recent targets:

David Westenberg from Piper Sandler set a target price of $200.0 on 06/11/2026
Rajesh Kumar from HSBC set a target price of $230.0 on 06/03/2026
Patrick Donnelly from Citigroup set a target price of $95.0 on 05/27/2026
Dan Leonard from RBC Capital set a target price of $200.0 on 05/15/2026
Kallum Titchmarsh from Morgan Stanley set a target price of $255.0 on 04/23/2026
Subbu Nambi from Guggenheim set a target price of $235.0 on 04/22/2026
Catherine Schulte from Baird set a target price of $245.0 on 04/22/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.